UroGen Pharma ( NASDAQ: URGN) closed Friday up ~43%, a week before the U.S. FDA is set to act on its NDA for UGN-102 (mitomycin), a treatment for a type of bladder cancer. It is not immediately clear ...

Despite robust fundamentals, Cintas trades at a premium valuation. Click here to find out why I am neutral on CTAS stock.

The U.S. Supreme Court on Friday allowed the Department of Government Efficiency ((DOGE)) access to the social security ...

Italy's Eni and Argentina's YPF signed an agreement to develop the Argentina liquefied natural gas export project, ...

HIO offers an attractive 11% yield, but its focus on high-yield, below-investment-grade debt increases risk. Click here to ...

Despite a recent earnings miss, Blue Owl Capital's revenue and AUM growth remain stellar, and future earnings should rebound.

"The first tranche of the program will cover up to $600 million (excluding customary transaction fees) and will start on June 9, 2025, and end no later than December 8, 2025", said the company, adding ...

Fielmann Group's multi-year investment cycle and international expansion have pressured margins and dividends. Click to read ...

Babcock & Wilcox Enterprises, Inc. is addressing debt and boosting orders amidst execution risks. Click for more on BW stock ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Palantir's DoD contracts, strong Q1 2025 growth, and competitive edge in AI-driven platforms make it a standout growth ...

Sunstone Hotel Investors, Inc., a stable REIT offers preferred shares with 7%+ yields. Click for my look at SHO and see if ...